Michael Papamichail
Overview
Explore the profile of Michael Papamichail including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
2074
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown 2nd T, Mittendorf E, Hale D, Myers 3rd J, Peace K, Jackson D, et al.
Breast Cancer Res Treat
. 2020 Apr;
181(2):391-401.
PMID: 32323103
Purpose: AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides were tested in...
2.
Jackson D, Trappey F, Clifton G, Vreeland T, Peace K, Hale D, et al.
Clin Immunol
. 2018 Jul;
195:28-35.
PMID: 30025819
Immunotherapy, using peptide-based cancer vaccines is being studied to assess its potential in breast cancer. Trials of HLA-restricted peptide vaccines have been difficult to enroll given HLA subtype restrictions. It...
3.
Voutsas I, Anastasopoulou E, Tzonis P, Papamichail M, Perez S, Baxevanis C
J Immunother Cancer
. 2016 Nov;
4:75.
PMID: 27891225
Background: Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently...
4.
Anastasopoulou E, Voutsas I, Papamichail M, Baxevanis C, Perez S
Oncoimmunology
. 2016 Sep;
5(7):e1178439.
PMID: 27622033
Realizing the basis for generating long-lasting clinical responses in cancer patients after therapeutic vaccinations provides the means to further ameliorate clinical efficacy. Peptide cancer vaccines stimulating CD4(+) T helper cells...
5.
Mittendorf E, Ardavanis A, Litton J, Shumway N, Hale D, Murray J, et al.
Oncotarget
. 2016 Sep;
7(40):66192-66201.
PMID: 27589688
GP2 is a HER2-derived, HLA-A2+ restricted peptide. Phase I studies showed GP2 administered with GM-CSF to be safe and immunogenic. Here we report the primary analysis of a prospective, randomized,...
6.
Anastasopoulou E, Voutsas I, Keramitsoglou T, Gouttefangeas C, Kalbacher H, Thanos A, et al.
Cancer Immunol Immunother
. 2015 Jun;
64(9):1123-36.
PMID: 26026288
Recently, several types of immunotherapies have been shown to induce encouraging clinical results, though in a restricted number of patients. Consequently, there is a need to identify immune biomarkers to...
7.
Baxevanis C, Papamichail M, Perez S
Cancer Immunol Immunother
. 2015 Feb;
64(4):401-8.
PMID: 25690791
Cancer vaccines as a modality of immune-based cancer treatment offer the promise of a non-toxic and efficacious therapeutic alternative for patients. Emerging data suggest that response to vaccination largely depends...
8.
Baxevanis C, Anastasopoulou E, Voutsas I, Papamichail M, Perez S
Expert Rev Mol Diagn
. 2014 Oct;
15(1):49-59.
PMID: 25345403
In order to be optimally efficacious, therapeutic cancer vaccines must induce robust tumor-specific CD8(+) cytotoxic T cells, which are responsible for tumor cell lysis. Unlike cytotoxic drugs, which act directly...
9.
Perez S, Anastasopoulou E, Papamichail M, Baxevanis C
Cancer Immunol Immunother
. 2014 Jul;
63(11):1141-50.
PMID: 25052849
A fundamental challenge in administering immunotherapies for cancer is the establishment of biomarkers that can predict patients' responsiveness to treatment. In this study, our aim was to predict the immunologic...
10.
Mahaira L, Katsara O, Pappou E, Iliopoulou E, Fortis S, Antsaklis A, et al.
Stem Cells Dev
. 2014 Jun;
23(20):2501-12.
PMID: 24915579
Mesenchymal stem cells (MSCs) are a population of cells harboring in many tissues with the ability to differentiate toward many different lineages. Unraveling the molecular profile of MSCs is of...